Crown Bioscience Launches New Translational Platforms For Metabolic Disease at Munich Diabetes Conference
Santa Clara, Calif., Sept. 6, 2016 — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, will be announcing the release of its new translational platforms for metabolic disease and nonalcoholic fatty liver disease (NASH) during the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), September 13-15, in Munich, Germany.
With the acquisition of PreClinOmics earlier this year, CrownBio has further expanded its translational technology platforms for cardiovascular and metabolic disease (CVMD) research, now offering models and services for every stage of the drug discovery process. CrownBio’s scientists will be available at booth B01 for the duration of EASD, and data will be presented at 11 a.m., 2 p.m. and 4 p.m. every day to introduce the company’s growing CVMD portfolio.
“We want to solve the most pressing scientific challenges in cardiovascular and metabolic disease research,” said Jean-Pierre Wery, Ph.D., CEO, Crown Bioscience. “Discussing our latest developments with the leaders in the industry will spark new ideas for the exploration of these complex diseases.”
In addition to introducing its newly developed CVMD translational platform featuring the ZDSD model of polygenic obesity and spontaneous diabetes, CrownBio will present new data on the development of preclinical solutions for NASH research, a therapeutic area with a high unmet need of models for pharmacological evaluation.
For more information on CrownBio’s growing portfolio of models and services for CVMD drug discovery, visit www.crownbio.com.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...